MedPage Today on MSN
Not all drugs approved for rheumatoid arthritis are equal for pain relief
The same analysis performed on data from the similarly designed SELECT-PsA 1 trial in psoriatic arthritis showed similar ...
Once-weekly semaglutide 1 mg was tied to a reduction in total daily insulin dose among adults with type 1 diabetes, ...
BullFrog AI's bfLEAP platform identified biomarkers linked to improved survival in pancreatic adenocarcinoma patients treated with glufosfamide. The study revealed four patient clusters, with one ...
SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the ...
South Korea: In a post hoc analysis of the randomized PULSAR trial, aflibercept 8 mg demonstrated noninferior visual outcomes ...
At the European Society of Cardiology (ESC) Congress 2025, findings from a post-hoc analysis of the SURMOUNT-5 trial (NCT05822830) were presented, comparing tirzepatide to semaglutide for their impact ...
In a post-hoc analysis of the ADVANCE and MOTIVATE phase III induction studies, along with the FORTIFY maintenance study, researchers evaluated the safety profile of risankizumab (Skyrizi) in patients ...
This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of newly developed drugs often don’t ...
Systematic assessment of tumor mutational burden calculation across different sequencing platforms and cancer types and its implication in clinical decision-making.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback